Publications by authors named "Daniel R Katzenberger"
Purpose Of Review: The purpose of this review is to highlight the evidence behind landmark trials involving these two novel drug classes in conjunction with a review of long-standing therapies used to improve cardiovascular (CV) outcomes among patients with peripheral artery disease (PAD) patients and type 2 diabetes mellitus (T2DM).
Recent Findings: Recently, societal guideline recommendations have expanded the management of T2DM to incorporate therapies with CV risk factor modification. This is due to CV outcome trials (CVOT) uncovering advantageous cardioprotective effects of several novel therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i).
Article Synopsis
- * A total of 939 patients were included in the study, and the electronic system involved sending alerts to identify patients who needed therapy and facilitating discussions between healthcare providers and patients.
- * Results showed that 36.7% of the patients responded to the alert by starting anticoagulation therapy, leading to a 23.6% increase in prescription rates compared to previous data.
Objective: The purpose of this review is to evaluate the efficacy and safety of colchicine after acute coronary syndrome (ACS).
Data Sources: English-language searches were made of MEDLINE and EMBASE from database inception through mid-June 2020.
Study Selection And Data Extraction: Randomized trials characterizing the effects of colchicine in ACS were considered.